BACKGROUND: As part of the development of the Neurocritical Care Society (NCS) Status Epilepticus (SE) Guidelines, the NCS SE Writing Committee conducted an international survey of SE experts. METHODS: The survey consisted of three patient vignettes (case 1, an adult; case 2, an adolescent; case 3, a child) and questions regarding treatment. The questions for each case focused on initial and sequential therapy as well as when to use continuous intravenous (cIV) therapy and for what duration. Responses were obtained from 60/120 (50%) of those surveyed. RESULTS: This survey reveals that there is expert consensus for using intravenous lorazepam for the emergent (first-line) therapy of SE in children and adults. For urgent (second-line) therapy, the most common agents chosen were phenytoin/fosphenytoin, valproate sodium, and levetiracetam; these choices varied by the patient age in the case scenarios. Physicians who care for adult patients chose cIV therapy for RSE, especially midazolam and propofol, rather than a standard AED sooner than those who care for children; and in children, there is a reluctance to choose propofol. Pentobarbital was chosen later in the therapy for all ages. CONCLUSION: There is close agreement between the recently published NCS guideline for SE and this survey of experts in the treatment of SE.
BACKGROUND: As part of the development of the Neurocritical Care Society (NCS) Status Epilepticus (SE) Guidelines, the NCS SE Writing Committee conducted an international survey of SE experts. METHODS: The survey consisted of three patient vignettes (case 1, an adult; case 2, an adolescent; case 3, a child) and questions regarding treatment. The questions for each case focused on initial and sequential therapy as well as when to use continuous intravenous (cIV) therapy and for what duration. Responses were obtained from 60/120 (50%) of those surveyed. RESULTS: This survey reveals that there is expert consensus for using intravenous lorazepam for the emergent (first-line) therapy of SE in children and adults. For urgent (second-line) therapy, the most common agents chosen were phenytoin/fosphenytoin, valproate sodium, and levetiracetam; these choices varied by the patient age in the case scenarios. Physicians who care for adult patients chose cIV therapy for RSE, especially midazolam and propofol, rather than a standard AED sooner than those who care for children; and in children, there is a reluctance to choose propofol. Pentobarbital was chosen later in the therapy for all ages. CONCLUSION: There is close agreement between the recently published NCS guideline for SE and this survey of experts in the treatment of SE.
Authors: Andreas van Baalen; Martin Häusler; Rainer Boor; Axel Rohr; Jürgen Sperner; Gerhard Kurlemann; Axel Panzer; Ulrich Stephani; Gerhard Kluger Journal: Epilepsia Date: 2010-03-18 Impact factor: 5.864
Authors: E P V Wilder-Smith; E C H Lim; H L Teoh; V K Sharma; J J H Tan; B P L Chan; B K C Ong Journal: Ann Acad Med Singap Date: 2005-08 Impact factor: 2.473
Authors: Peter Baxter; Antonia Clarke; Helen Cross; Brian Harding; Elaine Hicks; John Livingston; Robert Surtees Journal: Seizure Date: 2003-09 Impact factor: 3.184
Authors: Eileen Broomall; JoAnne E Natale; Michele Grimason; Joshua Goldstein; Craig M Smith; Celia Chang; Stephen Kanes; Michael A Rogawski; Mark S Wainwright Journal: Ann Neurol Date: 2014-11-11 Impact factor: 10.422
Authors: Jaideep Kapur; Jordan Elm; James M Chamberlain; William Barsan; James Cloyd; Daniel Lowenstein; Shlomo Shinnar; Robin Conwit; Caitlyn Meinzer; Hannah Cock; Nathan Fountain; Jason T Connor; Robert Silbergleit Journal: N Engl J Med Date: 2019-11-28 Impact factor: 91.245
Authors: Iván Sánchez Fernández; Nicholas S Abend; Satish Agadi; Sookee An; Ravindra Arya; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Margie Ream; James Riviello; Robert C Tasker; Tobias Loddenkemper Journal: Neurology Date: 2015-05-06 Impact factor: 9.910
Authors: Robert D Welch; Katherine Nicholas; Valerie L Durkalski-Mauldin; Daniel H Lowenstein; Robin Conwit; Prashant V Mahajan; Christopher Lewandowski; Robert Silbergleit Journal: Epilepsia Date: 2015-01-17 Impact factor: 5.864
Authors: Vincent Alvarez; Jong Woo Lee; M Brandon Westover; Frank W Drislane; Jan Novy; Mohamed Faouzi; Nicola A Marchi; Barbara A Dworetzky; Andrea O Rossetti Journal: Neurology Date: 2016-09-24 Impact factor: 9.910